Biomineralized Cu-Disulfiram nanoparticles Potentiate Colorectal cancer immunotherapy through synergistic cuproptosis and apoptosis

• ACOD achieves compartmentalized, stimuli-release codelivery of copper and disulfiram. • ACOD induces immunogenic cell death via chemo-chemodynamic apoptosis and cuproptosis. • ACOD activates robust anti-tumor immunity and potentiates αPD-L1 efficacy. • ACOD remodels tumor microenvironment potentially via chemotaxis pathways of immune cell. The aberrant tumor microenvironment (TME) in colorectal cancer (CRC) significantly limits the efficacy of current immunotherapy regimes. To address this challenge, the albumin-based copper (Cu) and Cu ionophores disulfiram (DSF) co-loaded nanoparticle (ACOD) is constructed through a biomineralization process. ACOD demonstrates tumor-targeted accumulation and releases Cu 2+ and DSF in response to acidic pH and elevated glutathione (GSH) respectively. After entering into mitochondria, Cu 2+ triggers cuproptosis, a novel and immunogenic Cu-dependent programmed cell death. Moreover, the Cu-diethyldithiocarbamate complex generated in situ by liberated Cu 2+ and DSF exerts a chemotherapeutic role. Besides, Cu 2+ can also arouse the chemodynamic therapy (CDT) via sequentially reacting with overexpressed GSH and H 2 O 2 . The chemotherapy and CDT synergistically promote tumor cell apoptosis. The combinative cuproptosis/apoptosis induction elicits robust immunogenic cell death, activates innate/adaptive immunity, and reprograms the immunosuppressive TME. Notably, ACOD upregulates tumor programmed cell death-ligand 1 (PD-L1) expression. Based on these efficacies, ACOD converts “immune-cold” CT26 tumors into “immune-hot” phenotypes and thus enhances therapeutic synergy with anti-PD-L1 antibodies. Transcriptomic analysis of tumor tissues via RNA sequencing elucidates ACOD’s anti-tumor mechanism. Along with its favorable biosafety, ACOD may serve as a multifunctional therapeutic strategy that overcomes TME-mediated immunotherapy outcome impairment in CRC through synergistic cuproptosis and apoptosis.

Authors

Institutions

Publication Details

Journal
Materials & Design
Published
2025-11-03
DOI
https://doi.org/10.1016/j.matdes.2025.115070
Citations
1
Primary Topic
Nanoplatforms for cancer theranostics
Type
article
Field-Weighted Citation Impact
0.67
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Biomineralized Cu-Disulfiram nanoparticles Potentiate Colorectal cancer immunotherapy through synergistic cuproptosis and apoptosis

Yun Seob Song, Junhao Huang, Hong‐Ming Hu, Mingli Hu et al.
1 citations
Materials & Design
Nanoplatforms for cancer theranostics
0.67
article

Biomineralized Cu-Disulfiram nanoparticles Potentiate Colorectal cancer immunotherapy through synergistic cuproptosis and apoptosis

Yun Seob Song, Junhao Huang, Hong‐Ming Hu, Mingli Hu, Guangzhen Qu, Pingping Hui, Jinlu Han, Yugang Wang, Jinghui Wang, Min Shi, Mengyan Chen, Qiong Wu, R. Shi
article en
1 citations

Abstract

• ACOD achieves compartmentalized, stimuli-release codelivery of copper and disulfiram. • ACOD induces immunogenic cell death via chemo-chemodynamic apoptosis and cuproptosis. • ACOD activates robust anti-tumor immunity and potentiates αPD-L1 efficacy. • ACOD remodels tumor microenvironment potentially via chemotaxis pathways of immune cell. The aberrant tumor microenvironment (TME) in colorectal cancer (CRC) significantly limits the efficacy of current immunotherapy regimes. To address this challenge, the albumin-based copper (Cu) and Cu ionophores disulfiram (DSF) co-loaded nanoparticle (ACOD) is constructed through a biomineralization process. ACOD demonstrates tumor-targeted accumulation and releases Cu 2+ and DSF in response to acidic pH and elevated glutathione (GSH) respectively. After entering into mitochondria, Cu 2+ triggers cuproptosis, a novel and immunogenic Cu-dependent programmed cell death. Moreover, the Cu-diethyldithiocarbamate complex generated in situ by liberated Cu 2+ and DSF exerts a chemotherapeutic role. Besides, Cu 2+ can also arouse the chemodynamic therapy (CDT) via sequentially reacting with overexpressed GSH and H 2 O 2 . The chemotherapy and CDT synergistically promote tumor cell apoptosis. The combinative cuproptosis/apoptosis induction elicits robust immunogenic cell death, activates innate/adaptive immunity, and reprograms the immunosuppressive TME. Notably, ACOD upregulates tumor programmed cell death-ligand 1 (PD-L1) expression. Based on these efficacies, ACOD converts “immune-cold” CT26 tumors into “immune-hot” phenotypes and thus enhances therapeutic synergy with anti-PD-L1 antibodies. Transcriptomic analysis of tumor tissues via RNA sequencing elucidates ACOD’s anti-tumor mechanism. Along with its favorable biosafety, ACOD may serve as a multifunctional therapeutic strategy that overcomes TME-mediated immunotherapy outcome impairment in CRC through synergistic cuproptosis and apoptosis.

Materials & DesignVol. 260
Nanchang University (CN), Shanghai Jiao Tong University (CN), Beijing Jiaotong University (CN), Beijing Chao-Yang Hospital, Capital Medical University (CN), First Affiliated Hospital of Jiangxi Medical College (CN), Tongren Hospital (CN), Second Affiliated Hospital of Nanchang University (CN)
Openalex Percentile: Top 25%
Nanoplatforms for cancer theranostics
0.67
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.